Vernalis Therapeutics has announced the re-launch of Moxatag (amoxicillin extended-release tablets) for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older.
Due to its extended-release formulation, Moxatag is dosed on a once-daily basis. The tablet formulation consists of three components, one immediate-release and two delayed-release, each containing amoxicillin. The three components are combined in a specific ratio to prolong the release of amoxicillin compared to immediate-release products.
Amoxicillin is similar to penicillin in its bacterial action against susceptible organisms during the stage of active multiplication. It acts though the inhibition of cell wall biosynthesis that leads to the death of the bacteria.
Moxatag is available as a 775mg tablet in 10- and 30-count bottles.
For more information visit VernalisTherapeutics.com.